GlassScriptPhysician profile
Jose A Martinez
NPI 1164426649
$4,596.41
in general payments reported to CMS, 2019-2025
26 companies · $1,029 in 2025
The $1,029 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $168 · 2021: $373 · 2022: $562 · 2023: $1,033 · 2024: $1,270 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284 · Education: $49.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.76 |
| Education | $49.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,000.96 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $966.41 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $465.62 | 2021-2025 | Dupixent |
| Genzyme Corporation | $399.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $281.98 | 2019-2025 | |
| Csl Behring | $275.74 | 2022-2025 | Andembry, Haegarda, Hizentra |
| Amgen INC. | $230.24 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $140.04 | 2021-2025 | Cuvitru |
| Biocryst US Sales Co., LLC | $138.77 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $111.11 | 2019-2024 | Xolair |
| Kaleo, INC. | $88.98 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $70.38 | 2023-2025 | |
| Abbvie INC. | $64.24 | 2022-2023 | |
| Incyte Corporation | $46.95 | 2022-2025 | Opzelura |
| Pharming Healthcare, INC. | $45.71 | 2025 | Ruconest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $43.43 | 2020-2023 | Odactra, Ragwitek, Grastek |
| Shionogi INC | $38.70 | 2019 | |
| Mylan Specialty L.P. | $30.61 | 2021 | |
| Grifols USA, LLC | $30.26 | 2024 | Xembify |
| Viatris Specialty LLC | $26.82 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.72 | 2022 | |
| Organon LLC | $18.15 | 2025 | |
| Octapharma USA, INC. | $17.32 | 2025 | Cutaquig |
| Cycle Pharmaceuticals INC | $16.80 | 2025 | Sajazir |
| Optinose US, INC. | $14.56 | 2019 | |
| Hikma Pharmaceuticals USA | $14.34 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.